Abbott Laboratories (ABT)
Health Care · $180B market cap · SEC CIK 0000001800
fundamentals score out of 100
Next reports on Oct 13, 2026, before the open, with analysts expecting $1.43 in earnings per share.
The case for ABT
- Generated $7.4B of free cash flow in FY2025, 17% of revenue.
- Revenue growing 8.1% year over year.
- Gross margin of 57% absorbs cost shocks.
- Moves less than the market (beta 0.54).
- Pays a modest 2.0% dividend.
The case against
- Earnings per share down 61.2%.
- Pricey at 33.2× earnings, against a long-run market average nearer 20×.
- Down 24.3% over the past year.
What the score is made of
Each factor is half a curve over reported figures and half a rank among the other Health Care companies (momentum is judged against fixed thresholds only), and the five are blended by weight. It describes the last filing and the current price. It is not a forecast.
| Valuewhat you pay for the earnings, sales, assets and cash | 48 |
|---|---|
| Growthhow fast revenue and earnings are moving, this year and over five | 23 |
| Profitabilityhow much of the revenue becomes profit, and how much of that is cash | 54 |
| Momentumhow the price has behaved lately | 46 |
| Stabilityhow violently it moves, what it owes and what it pays you | 79 |
- Each factor except momentum is half fixed thresholds, half rank among the 59 Health Care companies.
Key numbers
| Price / earnings | 33.2× |
|---|---|
| Price / book | 3.09× |
| Price / sales | 3.9× |
| Revenue growth (YoY) | +8.1% |
| EPS growth (YoY) | -61.2% |
| Gross margin | 57% |
| Operating margin | 16% |
| Net margin | 12% |
| Return on equity | 11% |
| Debt / equity | 0.64× |
| Current ratio | 1.38 |
| Dividend yield | 1.98% |
| Beta | 0.54 |
| 52-week range | $81.97 – $137.49 |
| Position in that range | 39% of the way up |
| 3-month return | +16.5% |
| 1-year return | -24.3% |
Five years of financials, as filed
Pulled from Abbott Laboratories's XBRL filings on SEC EDGAR. Italic rows are derived from the rows above.
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | $44.3B | $42.0B | $40.1B | $43.7B | $43.1B |
| Operating income | $8.1B | $6.8B | $6.5B | $8.4B | $8.4B |
| Net income | $6.5B | $13.4B | $5.7B | $6.9B | $7.1B |
| Operating cash flow | $9.6B | $8.6B | $7.3B | $9.6B | $10.5B |
| Capital expenditure | $2.2B | $2.2B | $2.2B | $1.8B | $1.9B |
| Total assets | $86.7B | $81.4B | $73.2B | $74.4B | $75.2B |
| Shareholder equity | $52.1B | $47.7B | $38.6B | $36.7B | $35.8B |
| Cash | $8.5B | $7.6B | $6.9B | $9.9B | $9.8B |
| Long-term debt | $9.9B | $12.6B | $13.6B | $14.5B | $17.3B |
| Free cash flow | $7.4B | $6.4B | $5.1B | $7.8B | $8.6B |
| Operating margin | 18.2% | 16.3% | 16.2% | 19.2% | 19.6% |
| Net margin | 14.7% | 31.9% | 14.3% | 15.9% | 16.4% |
| Diluted shares | 1.7B | 1.7B | 1.7B | 1.8B | 1.8B |
Share count is essentially flat over 4 years.
What Abbott Laboratories says it does
DEVELOPMENT OF BUSINESS Abbott Laboratories is an Illinois corporation, incorporated in 1900. Abbott’s* principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. On November 19, 2025, Abbott entered into a definitive agreement to acquire Exact Sciences Corporation (Exact Sciences), which is expected to enable Abbott to enter the cancer diagnostics market. The acquisition is subject to customary closing conditions, including the approval of Exact Sciences shareholders and obtaining the required regulatory clearances. NARRATIVE DESCRIPTION OF BUSINESS Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products These products include a broad line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States in…
Risk factors ABT lists in its 10-K
- Interest Expense and Interest (Income)
- Recently Issued Accounting Standards
- Recently Adopted Accounting Standards
- Income Taxes (Topic 740): Improvements to Income Tax Disclosures
- Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures
- Recent Accounting Standards Not Yet Adopted
- Income Statement (Subtopic 220-40): Reporting Comprehensive Income - Expense Disaggregation Disclosures
- Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements
- Financial Instruments and Risk Management
- Non-Publicly Traded Equity Securities
- Interest Rate Sensitive Financial Instruments
- Foreign Currency Sensitive Financial Instruments
- Fair and Carrying Value Receivable/ (Payable)
- Abbott Laboratories and Subsidiaries